Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Dermatol. 2010 May;22(2):186-90. doi: 10.5021/ad.2010.22.2.186. Epub 2010 May 18.

CD4-/CD56+/CD123+ Hematodermic Neoplasm Showing Early Liver Metastasis.

Author information

1
Department of Dermatology, College of Medicine, Dong-A University, Busan, Korea.

Abstract

Hematodermic neoplasm (HN) is a clinically aggressive neoplasm with a high incidence of cutaneous involvement and a risk of leukemic dissemination. In the recent WHO-EORTC classification, the term blastic natural killer cell lymphoma has been replaced with CD4+/CD56+ HN because of its derivation from a plasmacytoid dendritic cell precursor. Cases of HN that completely lack CD4 or CD56 expression, therefore represents a diagnostic problem. A 68-year-old Korean male was diagnosed with CD4-/CD56+ HN and treated with hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) at initial treatment, and then switched to high dose methotrexate/cytarabine. His disease relapsed and resulted in death from bone and brain disease 6 months after complete clinical remission, despite diagnostic workups, including a radioisotope liver scan and ultrasound-guided fine needle aspiration biopsy. Further cytogenetic studies such as comparative genomic hybridization could elucidate the genetic mechanisms in the development and progression of lymphomas. We report an unusual case of 'CD4-/CD56+/CD123+ HN' showing early liver metastasis.

KEYWORDS:

CD4-/CD56+/CD123+ hematodermic neoplasm; Early liver metastasis

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Korean Dermatological Association Icon for PubMed Central
    Loading ...
    Support Center